PHENACETIN

US Previously Marketed

First marketed in 1887

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H13NO2
Molecular Weight	179.2161
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOc1ccc(cc1)N=C(C)O

InChI

InChIKey=CPJSUEIXXCENMM-UHFFFAOYSA-N

InChI=1S/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C10H13NO2
Molecular Weight	179.2161
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/books/NBK304337
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18140117 | https://www.ncbi.nlm.nih.gov/pubmed/3552585 | https://www.ncbi.nlm.nih.gov/pubmed/12242329 | https://www.ncbi.nlm.nih.gov/pubmed/14592552

Phenacetin was used as an analgesic and fever-reducing drug in both human and veterinary medicine for many years. Since a major portion of a dose of phenacetin is rapidly metabolised to paracetamol, it seems possible that phenacetin owes some of its therapeutic activity to its main metabolite, paracetamol, whereas its most troublesome side effect (methaemoglobinaemia) is due to another metabolite, p-phenetidine. Phenacetin was shown to inhibit cyclooxygenase (COX)-3, a cyclooxygenase-1 variant while p-phenetidine potently inhibits both COX-1 and COX-2. There is sufficient evidence in humans for the carcinogenicity of analgesic mixtures containing phenacetin. Analgesic mixtures containing phenacetin cause cancer of the renal pelvis, and of the ureter. Phenacetin was withdrawn from many analgesic mixtures long before the legal ban in several countries.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Prostaglandin G/H synthase 1 29 Target ID: Q8HZR1 Gene ID: 403544.0 Gene Symbol: PTGS1 Target Organism: Canis lupus familiaris (Dog) (Canis familiaris) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12242329	Inhibitor 7728	102.0 µM [IC50]
Cyclooxygenase-1 124 Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14592552	Inhibitor 7728
Cyclooxygenase-2 189 Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14592552	Inhibitor 7728

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 580 Sources: https://www.ncbi.nlm.nih.gov/books/NBK304337 https://www.ncbi.nlm.nih.gov/pubmed/3552585	Primary		Withdrawn	Phenacetin Approved Use Phenacetin was used as an analgesic and fever-reducing drug in both human and veterinary medicine for many years. Launch Date -2.61930248E12

C_max

Value	Dose	Analyte	Population
6.9 μg/mL EXPERIMENT https://journals.lww.com/drug-monitoring/Abstract/1998/08000/Effect_of_Active_and_Passive_Cigarette_Smoking_on.2.aspx	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	ACETAMINOPHEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
13.5 μg/mL EXPERIMENT https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/j.1552-4604.1974.tb02323.x	1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.48 μg/mL EXPERIMENT https://www.jstage.jst.go.jp/article/jscpt1970/19/4/19_4_767/_pdf	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.84 μg/mL EXPERIMENT https://www.jstage.jst.go.jp/article/jscpt1970/19/4/19_4_767/_pdf	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.5 μg/mL EXPERIMENT https://journals.lww.com/drug-monitoring/Abstract/1998/08000/Effect_of_Active_and_Passive_Cigarette_Smoking_on.2.aspx	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
40.4 μg × h/mL EXPERIMENT https://journals.lww.com/drug-monitoring/Abstract/1998/08000/Effect_of_Active_and_Passive_Cigarette_Smoking_on.2.aspx	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	ACETAMINOPHEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20.72 μg × h/mL EXPERIMENT https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/j.1552-4604.1974.tb02323.x	1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.58 μg × h/mL EXPERIMENT https://www.jstage.jst.go.jp/article/jscpt1970/19/4/19_4_767/_pdf	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.84 μg × h/mL EXPERIMENT https://www.jstage.jst.go.jp/article/jscpt1970/19/4/19_4_767/_pdf	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.3 μg × h/mL EXPERIMENT https://journals.lww.com/drug-monitoring/Abstract/1998/08000/Effect_of_Active_and_Passive_Cigarette_Smoking_on.2.aspx	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
2.6 h EXPERIMENT https://journals.lww.com/drug-monitoring/Abstract/1998/08000/Effect_of_Active_and_Passive_Cigarette_Smoking_on.2.aspx	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	ACETAMINOPHEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.6 h EXPERIMENT https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/j.1552-4604.1974.tb02323.x	1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.98 h EXPERIMENT https://www.jstage.jst.go.jp/article/jscpt1970/19/4/19_4_767/_pdf	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.1 h EXPERIMENT https://www.jstage.jst.go.jp/article/jscpt1970/19/4/19_4_767/_pdf	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.9 h EXPERIMENT https://journals.lww.com/drug-monitoring/Abstract/1998/08000/Effect_of_Active_and_Passive_Cigarette_Smoking_on.2.aspx	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENACETIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
70% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23607050/			PHENACETIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1.5 g 1 times / day multiple, oral Studied dose Dose: 1.5 g, 1 times / day Route: oral Route: multiple Dose: 1.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6025701/	unhealthy, 34 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 34 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/6025701/	Other AEs: Nephropathy... Other AEs: Nephropathy Sources: https://pubmed.ncbi.nlm.nih.gov/6025701/
250 mg multiple, oral Studied dose Dose: 250 mg Route: oral Route: multiple Dose: 250 mg Co-administed with:: acetylsalicylic acid(250 mg; 40 years) codeine phosphate(10 mg; 40 years) Sources: https://pubmed.ncbi.nlm.nih.gov/5915057/	unhealthy, 54 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 54 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/5915057/	Other AEs: Nephropathy... Other AEs: Nephropathy Sources: https://pubmed.ncbi.nlm.nih.gov/5915057/
1 g 1 times / day multiple, oral Studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/831357/	unhealthy, 56 years n = 1 Health Status: unhealthy Condition: knee pain Age Group: 56 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/831357/	Other AEs: Transitional cell carcinoma... Other AEs: Transitional cell carcinoma Sources: https://pubmed.ncbi.nlm.nih.gov/831357/
625 mg 1 times / day multiple, oral (mean) Studied dose Dose: 625 mg, 1 times / day Route: oral Route: multiple Dose: 625 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21318943/	unhealthy, 85 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 85 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21318943/	Other AEs: Urothelial carcinoma... Other AEs: Urothelial carcinoma Sources: https://pubmed.ncbi.nlm.nih.gov/21318943/
0.9 g 4 times / day multiple, oral Studied dose Dose: 0.9 g, 4 times / day Route: oral Route: multiple Dose: 0.9 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5327673/	healthy, age 18 to 44 years n = 10 Health Status: healthy Age Group: age 18 to 44 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/5327673/	Other AEs: Nephritis NEC... Other AEs: Nephritis NEC (20%) Sources: https://pubmed.ncbi.nlm.nih.gov/5327673/

AEs

AE	Significance	Dose	Population
Nephropathy		1.5 g 1 times / day multiple, oral Studied dose Dose: 1.5 g, 1 times / day Route: oral Route: multiple Dose: 1.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6025701/	unhealthy, 34 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 34 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/6025701/
Nephropathy		250 mg multiple, oral Studied dose Dose: 250 mg Route: oral Route: multiple Dose: 250 mg Co-administed with:: acetylsalicylic acid(250 mg; 40 years) codeine phosphate(10 mg; 40 years) Sources: https://pubmed.ncbi.nlm.nih.gov/5915057/	unhealthy, 54 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 54 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/5915057/
Transitional cell carcinoma		1 g 1 times / day multiple, oral Studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/831357/	unhealthy, 56 years n = 1 Health Status: unhealthy Condition: knee pain Age Group: 56 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/831357/
Urothelial carcinoma		625 mg 1 times / day multiple, oral (mean) Studied dose Dose: 625 mg, 1 times / day Route: oral Route: multiple Dose: 625 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21318943/	unhealthy, 85 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 85 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21318943/
Nephritis NEC	20%	0.9 g 4 times / day multiple, oral Studied dose Dose: 0.9 g, 4 times / day Route: oral Route: multiple Dose: 0.9 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5327673/	healthy, age 18 to 44 years n = 10 Health Status: healthy Age Group: age 18 to 44 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/5327673/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601	substrate 936	substrate 1118

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1A2 972 CYP2E1 606 CYP1A1 325 CYP2C19 910

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 325	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10421611/ Page: 1.0	inconclusive
CYP2C19 910	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10421611/ Page: 1.0	inconclusive
CYP2D6 1118	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10421611/ Page: 1.0	inconclusive
CYP3A4 1601	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10421611/ Page: 1.0	inconclusive
CYP1A2 972	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC298137/pdf/pnas00287-0044.pdf#page=1 Page: 1.0	major	yes (co-administration study) Comment: cigarette smoking induced CYP1A2 and increased O-deethylase activity Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC298137/pdf/pnas00287-0044.pdf#page=1 Page: 1.0
CYP2C9 936	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10627170/ Page: 1.0	minor
CYP2E1 606	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10421611/ Page: 1.0	minor

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8050	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8050
ChemicalBook	CB44796969	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB44796969
ChemicalBook	CB6141828	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6141828
MolPort	MolPort-000-626-710	https://www.molport.com/shop/molecule-link/MolPort-000-626-710
Selleck Chemicals	phenacetin	http://www.selleckchem.com/products/phenacetin.html
ZINC	ZINC000000000602	http://zinc15.docking.org/substances/ZINC000000000602
eMolecules	490668	https://www.emolecules.com/cgi-bin/more?vid=490668

PubMed

Title	Date	PubMed
IS PHENACETIN A NEPHROTOXIN?A REPORT ON TWENTY-THREE USERS OF THE DRUG.	1964 Aug	14180501
[Determination of three components in compound chlorophenamine tablet by iterative target transformation factor analysis].	2001 Apr	12947639
[Simultaneous determination of aspirin, phenacetin and caffeine in compound APC by derivative ratio UV adsorption spectrum method].	2001 Aug	12945285
Renal PGE2 production in the human and rat following phenacetin, acetaminophen and p-aminophenol.	2002	14632321
Drug-induced hepatitis with hepatic granuloma due to saridon.	2002	12522541
Alteration of phenacetin pharmacokinetics after experimental spinal cord injury.	2002	12434508
Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.	2002	12383041
Decreased hepatic drug metabolising enzyme activity in rats with nitrosamine-induced tumours.	2002	12222751
Validated HPLC method for determination of chlorzoxazone in human serum and its application in a clinical pharmacokinetic study.	2002 Dec	12561241
Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions.	2002 Dec	12433797
[Simultaneous determination of four components in the compound child phenobarbital tablet using ultraviolet spectrophotometry].	2002 Feb 28	12575249
Hydrogen bonding with adsorbent during storage governs drug dissolution from solid-dispersion granules.	2002 Nov	12458672
Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs.	2002 Nov	12388633
Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction.	2002 Nov 25	12401374
Monolithic silica rod liquid chromatography with ultraviolet or fluorescence detection for metabolite analysis of cytochrome P450 marker reactions.	2002 Nov 25	12401345
Hospitalized poisonings after renal transplantation in the United States.	2002 Nov 26	12450414
Renal papillary necrosis.	2002 Nov-Dec	12512867
COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.	2002 Oct 15	12242329
Polymer particle erosion controlling drug release. II. Swelling investigations to clarify the release mechanism.	2002 Oct 24	12429482
Correlation between induction of DNA fragmentation in urinary bladder cells from rats and humans and tissue-specific carcinogenic activity.	2002 Sep 30	12204548
Epidemiology of non-steroidal anti-inflammatory drugs and cancer.	2003	12795046
Analgesics and renal disease in the postphenacetin era.	2003 Aug	12900824
'Open access' generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies.	2003 Dec	14742145
Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain.	2003 Dec 9	14640697
Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A.	2003 Feb 14	12586202
High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry.	2003 Jan 1	12467917
Simultaneous liquid chromatography-tandem mass spectrometric determination of albendazole sulfoxide and albendazole sulfone in plasma.	2003 Jan 5	12450544
Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation.	2003 Jul	12814974
Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones.	2003 Jul	12814970
Caffeine as a promoter of analgesic-associated nephropathy--where is the evidence?	2003 Jun	12803578
[Novel potential uses of thalidomide in the management of pain? A review of the literature].	2003 Jun	12789488
Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro.	2003 Jun 15	14592552
Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.	2003 Nov	14570767
Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis.	2003 Oct 31	14588079
HPLC analyses and pharmacokinetic studies of baicalin and oxymatrine in rabbits.	2003 Sep	14531454
Assessment of tableting properties using infinitesimal quantities of powdered medicine.	2003 Sep 16	12954193
Induction of diphenytriazol on cytochrome CYP1A.	2004 Apr	15066225
Analgesic nephropathy in Hungary: the HANS study.	2004 Apr	15031338
Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes.	2004 Apr 16	15043991
Phenacetin and cocaine in a body packer.	2004 Apr 20	15066715
Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.	2004 Feb	14610241
Functional characterization of four allelic variants of human cytochrome P450 1A2.	2004 Feb 1	14725854
Interaction of cyclooxygenase isoenzymes, nitric oxide, and afferent neurons in gastric mucosal defense in rats.	2004 Jan	14569068
Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes.	2004 Jan	14563787
Antipyretic therapy.	2004 Jan 1	14766422
Validated assays for human cytochrome P450 activities.	2004 Jun	15155557
Evaluation of the patient with hematuria.	2004 Mar	15049581
In vitro metabolism and inductive or inhibitive effect of DL111 on rat cytochrome P4501A enzyme.	2004 Mar 15	15013813
Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.	2004 Mar-Apr	15200157
[Prevention of bladder cancer].	2004 May	15150694

Patents

Sample Use Guides

In Vivo Use Guide

Analgesic mixtures containing phenacetin were previously marketed as tablets or capsules containing between 150 and 300 mg phenacetin. Common combinations were: 150 mg phenacetin, 230 mg aspirin, and 15 or 30 mg caffeine; or 150 mg phenacetin, 230 mg aspirin, 30 mg caffeine, and 8, 15, 30, or 60 mg codeine phosphate. Phenacetin alone was also available in 250 and 300 mg doses as tablets, and up to 500 mg doses as powder. The usual dose was 300 mg 4–6 times per day, and the daily dose was not to exceed 2 g

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Jun 26 14:50:06 UTC 2021` Edited by `admin` on `Sat Jun 26 14:50:06 UTC 2021`
Record UNII	ER0CTH01H9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PHENACETIN

Official Name

English

PHENACETIN [VANDF]

Common Name

English

4-ETHOXY-1-ACETYLAMINOBENZENE

Systematic Name

English

FENIDINA

Common Name

English

NSC-7651

Code

English

PHENACETIN [MART.]

Common Name

English

ACETAMIDE, N-(4-ETHOXYPHENOL)-

Common Name

English

PHENACETIN [JAN]

Common Name

English

ACETPHENETIDIN

Common Name

English

KALMIN

Common Name

English

PHENACETIN [INCI]

Common Name

English

PHENACETIN MELTING POINT STANDARD

Common Name

English

PHENACETIN [MI]

Common Name

English

PHENACETINUM

Common Name

English

PHENACETINUM [HPUS]

Common Name

English

PHENACETIN [USP-RS]

Common Name

English

PHENACETIN [IARC]

Common Name

English

PHENAZETIN

Common Name

English

PHENACETIN [INN]

Common Name

English

P-ACETOPHENETIDIDE

Common Name

English

PHENACETIN [HSDB]

Common Name

English

ACETOPHENETIDIN

Common Name

English

PHENACETIN [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N02BE53